8/F, 35 QRC Building, No.35 Queen's Road, Central, Hong Kong
Home > All Medicines > Breast Cancer > Enhertu (fam trastuzumab deruxtecan nxki)

Enhertu (fam trastuzumab deruxtecan nxki)

  • General name:
  • Product name: Enhertu
  • Alias:
    DS 8201trastuzumab deruxtecan
  • Indications: Enhertu (fam-trastuzumab deruxtecan-nxki) is a medication used for the treatment of adult patients with advanced HER+ breast cancer or with advanced HER2+ stomach (gastric) or gastroesophageal junction (GEJ) cancer.
  • Manufacturer: Daiichi Sankyo
  • Price: Welcome to inquiry

Enhertu (fam trastuzumab deruxtecan nxki) is a HER2-directed antibody and topoisomerase inhibitor conjugate. Enhertu (fam trastuzumab deruxtecan nxki) is an antibody-drug conjugate (ADC) composed of three components: 1) a humanized anti-HER2 IgG1 monoclonal antibody (mAb), covalently linked to 2) a topoisomerase inhibitor, via 3) a tetrapeptide-based cleavable linker. Deruxtecan is composed of a protease-cleavable maleimide tetrapeptide linker and the topoisomerase inhibitor, DXd, which is an exatecan derivative.

Enhertu (fam trastuzumab deruxtecan nxki)

---Indications and Usage---

Enhertu is a HER2-directed antibody and topoisomerase inhibitor conjugate indicated for the treatment of:

1. Adult patients with unresectable or metastatic HER2-positive breast cancer who have received a prior anti-HER2-based regimen either:

    in the metastatic setting, or

    in the neoadjuvant or adjuvant setting and have developed disease recurrence during or within six months of completing therapy. 

2. Adult patients with locally advanced or metastatic HER2-positive gastric or gastroesophageal junction adenocarcinoma who have received a prior trastuzumab-based regimen. 

Disclaimer: The services of Hong Kong Magicure Medical Center do not replace a physician-patient relationship and are not intended as medical advice. Hong Kong Magicure Medical Center provides patients and physicians with new medicine options by providing safe and secure access to approved medicines from other countries. We only provide this service after the patient and physician have made a professional decision on the treatment.